Two neurologists at Wayne State University School of Medicine will start recruiting patients in May for a clinical trial testing the efficacy and safety of the drug perampanel in treating refractory status epilepticus. .
Patients with prolonged seizures after treatment with benzodiazepines and antiepileptic drugs are said to have refractory status epilepticus.
Wazim Mohamed, M.D., Ph.D., Associate Professor of Neurology and Neurosurgery, and Maysaa Basha, M.D., Ph.D., Interim Chair and Associate Professor of Neurology, were co-investigators of the two-year study and explored perampanel’s unique mechanism of action. is the key to its efficacy in refractory status epilepticus.
Status epilepticus is estimated to be refractory in about 30% of cases, is associated with increased morbidity and mortality, and requires continuous EEG monitoring to guide treatment, says Dr. Mohamed said. It is found in all age groups and has approximately 200,000 cases annually in the United States.
Dr. Mohammed is Director of the Neurocritical Care Fellowship Training Program at the Detroit Medical Center. He completed his residency training at WSU. He is also the Medical Director of the Neuro-Critical Care Unit at Detroit Reception Hospital.
“The mortality rate associated with refractory status epilepticus is as high as 40%,” he said. “The success rate of treating refractory status epilepticus depends on many factors, including the underlying cause, the age and general health of the patient, and the type and timing of treatment used. Patients with status epilepticus have a low success rate of 40%, and early diagnosis and treatment have been reported to improve prognosis.”
Perampanel is a selective, non-competitive AMPA receptor antagonist.
“We hypothesize that perampanel may help achieve successful withdrawal from intravenous anesthetics without recurrent seizures in patients with refractory status epilepticus,” said Dr. Mohamed.
“These patients often require intravenous anesthetics and have to undergo intubation and mechanical ventilation,” added Dr. Mohamed. “The next step in their course of treatment is to wean the intravenous anesthetic without recurring seizures. , hypothesizes that we can successfully wean off the anesthetic without recurring seizures.”
For more information on the clinical trial, please visit https://clinicaltrials.gov/ct2/show/NCT05684978.